Genethon Presents Two Year Consolidated Results of Its Gene Therapy Trial for Duchenne Muscular Dystrophy: Maintenance of Motor Functions and Significant, Sustained Reduction in CPK Levels in Patients Treated at the Effective Dose at ASGCT 2025
PARIS--(BUSINESS WIRE)--May 19, 2025--
Genethon unveiled the 2-year follow-up data from its GNT0004 gene therapy clinical trial for Duchenne Muscular Dystrophy (GNT-016-MDYF) at the annual meeting of the American Society of Gene & Cell Therapy (ASGCT) in New Orleans, May 13 – 17, 2025. Five patients, aged 6 to 10 years, were treated, 2 at the first dose level and 3 at the second dose level (3x10¹³ vg/kg). The initial part of the clinical trial aimed at selecting the optimal dose (dose escalation phase), evaluating the tolerance and preliminary efficacy of the treatment and determined the effective dose for the pivotal phase of the GNT-016-MDYF trial, which is expected to start in mid-2025 (3x10¹³ vg/kg).
Genethon CEO Frederic Revah observed, 'The results of our gene therapy GNT0004 are very positive in patients treated at the dose of 3x10¹³ vg/kg, both in terms of microdystrophin expression and clinical efficacy criteria. Besides these results, the advantage of our product lies in the selected dose for the pivotal phase, which is lower than those used in other gene therapy trials for Duchenne Muscular Dystrophy. We are currently preparing the pivotal phase that we will conduct in Europe and the US.'
Safety, efficacy, and pharmacodynamic results show good tolerance of GNT0004 associated with transient immunological prophylactic treatment, as well as efficacy data in terms of microdystrophin expression, CPK reduction, and clinical criteria (NSAA, timed tests). Patients treated at the effective dose show prolonged improvement or stabilization of motor functions and significant persistent reduction in creatine kinase (CPK) levels, a key marker of muscle damage.
One-year post-treatment, the comparison of the three patients treated at the effective dose with a group of 34 untreated patients, matched by age and followed in the same centers and by the same practitioners, shows a difference of +4.7 points in the score obtained using the internationally recognized clinical evaluation scale NSAA between treated and untreated patients.
At 24 months post-treatment, key observations include:
About GNT0004 and the trial
The GNT0004 gene therapy is composed of an AAV8 (adeno-associated virus) vector and the optimized hMD1 transgene, a shortened but functional version of the gene encoding dystrophin, the protein deficient in people with DMD. This vector is designed to be expressed in muscle tissue and also in the heart, thanks to a tissue-specific Spc5-12 promoter sequence. GNT0004 is administered by a single intravenous injection. It was developed by Genethon, in partnership with the teams of Prof. Dickson (University of London, Royal Holloway) and the Institut de Myologie (Paris). The trial, sponsored by Genethon, combines Phases 1/2/3, a dose-escalation phase followed by a pivotal phase at the dose finally chosen. The trial is being carried out in France and the UK and includes boys aged 6 to 10 with DMD who have retained their ability to walk.
About Duchenne muscular dystrophy
DMD is a rare, progressive genetic disease affecting all the body's muscles, and mainly boys (1 in 5000). It is due to abnormalities in the gene responsible for producing dystrophin, a structural protein essential for the stability of muscle fiber membranes and their metabolism. The absence of dystrophin leads to progressive degeneration of skeletal and cardiac muscles, loss of walking and respiratory capacity, cardiomyopathy and death between the ages of 20 and 40.
About Genethon
A pioneer in the discovery and development of gene therapies for rare diseases, Genethon is a nonprofit organization created by the AFM-Téléthon. The first gene therapy to treat spinal muscular atrophy, incorporating technologies developed at Genethon, is marketed worldwide. With over 240 scientists and professionals, Genethon pursues its goal of developing innovative therapies that change the lives of patients suffering from rare genetic diseases. Thirteen products from Genethon's R&D or collaborations are in clinical trials for diseases of the liver, blood, immune system, muscles and eyes. A further seven products could enter clinical trials in the next five years. To find out more visit: http://www.genethon.com/.View source version on businesswire.com:https://www.businesswire.com/news/home/20250519497866/en/
CONTACT: Press contact:
Stephanie Bardon
[email protected]
06.45.15.95.87
KEYWORD: EUROPE UNITED STATES NORTH AMERICA FRANCE WASHINGTON
INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH GENETICS PHARMACEUTICAL CLINICAL TRIALS
SOURCE: Genethon
Copyright Business Wire 2025.
PUB: 05/19/2025 05:30 AM/DISC: 05/19/2025 05:31 AM
http://www.businesswire.com/news/home/20250519497866/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
2 hours ago
- Medscape
Limited Survival Benefit With Expanded Kidney Donor Criteria
VIENNA — The use of expanded-criteria donors for kidney transplantation in older and high-risk recipients did not provide the same survival benefit as the use of standard donors, according to an analysis of data from more than 64,000 individuals in the European Renal Association (ERA) Registry, using target trial emulation. 'When determining who is a suitable transplant candidate, we shouldn't only focus on the patient alone, because the outcomes will also depend on donor quality,' said study presenter Rachel Hellemans, MD, PhD, a nephrologist at Antwerp University Hospital, Belgium. 'Of course, ideally, we would like to give a transplant to everyone, but shortage is a reality,' she continued. The possibilities for older patients to receive a standard-criteria donor kidney depend on local allocation systems and waiting times. Waiting an extended period for a transplant carries the risk of clinical deterioration, Hellemans pointed out, and patients may want to 'settle for an expanded-criteria donor kidney — although, in general, these kidneys perform less well.' 'Even in the absence of a true survival difference, patients may still value this kind of transplantation to improve the quality of their remaining life years,' she said. But clinicians need to be careful 'to interpret and communicate the results of our study' she cautioned, 'because, despite a very thorough pretransplant workup,' and 'careful decision-making as a transplant team, there remains an element of unpredictability and some very real risks, especially in the early post-transplant period.' Exploring the Margins of Survival Benefits The research presented here at the 62nd ERA Congress 2025 was based on an analysis of data on more than 64,000 individuals on the European Renal Association (ERA) Registry. 'Transplantation is, no doubt, the optimal treatment strategy for many of our patients with kidney failure,' said Hellemans, 'and it often leads to substantially better survival compared to continued dialysis, but its successes have also made us push the boundaries.' She pointed out that, due to a lack of suitable donor organs, clinicians have increasingly turned to less-than-ideal donors, such as those who are older, have more comorbidities, or who have died due to circulatory disorders. On the other hand, patients on dialysis now have improved survival, said Hellemans. Therefore, the question becomes: 'Where do the margins lie for the survival benefit with transplantation?' 'Although this may sound like a simple question,' she continued, 'it's actually a very difficult one to answer.' Ideally, a research question like this would be answered with a randomized control trial (RCT), 'which is impossible for ethical and practical reasons.' The next best step is to turn to registry data, but this is fraught with methodological pitfalls. Hellemans said that approximately half of such studies in the field suffer from avoidable biases, likely leading to an overestimation of the true benefit of transplantation. Moreover, the most recent comprehensive assessment of the impact of recipient age and comorbidities, and donor quality on mortality risk in older patients, was published in 2013, and Hellemans pointed out that this is a fast-evolving field, and so regular updates are required. The researchers therefore turned to the ERA Registry, which contains data on 64,013 adults from France, Catalonia (in Spain), Denmark, Norway, and the United Kingdom who were on dialysis and wait-listed for a first deceased donor kidney transplant between 2000 and 2019. The study investigators looked at 5-year survival with transplantation vs continued dialysis, stratified by donor type: standard-criteria donor kidneys, or those from donors younger than 60 years of age without significant risk factors for poor kidney function; and expanded-criteria donor kidneys, which includes all donors aged ≥ 60 years, and aged 50-59 years who had at least two of the following: a history of arterial hypertension, death from cerebrovascular accident, and/or last serum creatinine > 1.5 mg/dL. The recipients were also stratified by age and presence of comorbidities, namely diabetes, and a history of cardiovascular disease. To overcome the limitations of using registry data, the researchers turned to a methodological framework known as target trial emulation. Here, they treated their observational data as if it was from an RCT, in which transplantation was considered the intervention, and each transplant launched one of a series of sequential trials comparing the outcome with that seen for patients who remained on dialysis. They then controlled for country, time on dialysis prior to wait-listing, calendar year of transplantation, patient sex, cause of kidney failure, and diabetes. This way, Hellemans explained, they could avoid the biases that normally come with registry-based studies. Provided there is no important and measured confounding, target trial emulation can 'achieve a level of evidence that closely approximates that of a true RCT.' Standard Criteria Donor vs Extended Criteria Donor The results showed that, no matter the recipient's age, the 5-year adjusted survival rate was substantially better for transplant patients who received a standard-criteria donor organ than those who remained on dialysis. However, when the researchers turned to expanded-criteria donors, they found that the survival benefit from transplant decreased with increasing recipient age — to the extent that, among those who received a donor organ after circulatory death, the advantage all but disappeared. Among patients aged 75 years and older, 5-year survival rates for recipients who received kidneys from extended criteria donors were estimated at 57%–58%, only slightly higher than the 54% in those who remained on dialysis. A similar pattern was seen when looking at recipients with diabetes and those with cardiovascular disease: standard-criteria donors were associated with a survival benefit with transplant over remaining on dialysis — no matter the recipient's age — while the benefit dropped off sharply with increasing age in patients receiving expanded-criteria donor organs. A key factor was the increased early post-transplant mortality observed in older patients receiving expanded criteria kidney donations, Hellemans reported. There was a sharp rise in mortality risk compared with staying on dialysis in the first 10 months after undergoing transplant, followed by a drop-off in risk until, at 5 years, the hazard ratio for death was 1.01 (95% CI, 0.74-1.36) for the two approaches, she explained. Limitations of the study include the heterogeneous nature of the donor population, and potential residual confounding factors due to the lack of information on the functional status of the patients, said Hellemans. In addition, the presence of diabetes and cardiovascular disease were recorded only at the time of wait-listing, thus they did not include incident cases during follow-up. Moreover, 5-year survival as an outcome has its limitations, she pointed out, as few patients remained on dialysis beyond this timeframe. Informed Discussions With Patients 'The breadth of data we could access via the ERA Registry showed that the survival advantage of a transplant plateaus for the very oldest or highest-risk patients who are likely to receive an expanded-criteria or circulatory-death donor kidney,' said Vianda Stel, PhD, associate professor in the Department of Medical Informatics at Amsterdam UMC, the Netherlands, and director of the ERA Registry, in a press release. 'This arms clinicians with guidance to have informed discussions with their patients. The message is not 'don't transplant older people,' ' she said, but rather 'be open about uncertainty when the numbers say benefit may be marginal.' 'We were always convinced that we can give a benefit by giving a transplant to every patient on the waiting list,' Christoph Wanner, MD, PhD, professor of medicine and head of the Division of Nephrology, University of Würzburg, Germany, told Medscape Medical News . 'And now we see that, in those aged 75 years, they will not have a benefit with the expanded donor criteria.' He said that the 'big question' is whether the current findings will affect clinical decision-making. 'I think dialysis doctors will respond to this and maybe keep patients on dialysis for various reasons and not push them into transplant. This new data give us the justification' to make that argument. Given that the pool of available organs cannot be expanded, Wanner believes that current waiting lists could be rationalized so that 'the organs that are available could be directed to a smaller proportion of patients, and therefore people would benefit' from lower wait times. Daniel W. Coyne, MD, professor of medicine, Nephrology/Internal Medicine at Washington University in St. Louis, Missouri, commented on X (formerly Twitter) that the benefit with expanded-criteria donation decreases with older age 'is not what my transplant group is telling our patients in the US.' He added: 'We need this [trial] emulation in US data.' | content The research received no specific grant. Hellemans, Stel, Wanner, and Coyne reported no relevant financial relationships.
Yahoo
4 hours ago
- Yahoo
European Health IT Leaders Look to Denmark and Finland as Models for EHR Interoperability and Patient Access, Black Book Survey Reveals
Ahead of Next Week's HIMSS 25 Europe in Paris, Attendees Look to Top Interoperability Vendors for Solutions PARIS, FRANCE / / June 7, 2025 / Black Book Market Research today released findings from its latest survey highlighting the influence of Denmark and Finland on Electronic Health Record (EHR) interoperability and patient access initiatives across Europe. Conducted among 312 healthcare IT leaders from 8 higher tech-adoption European nations, the study underscores the strategic shift among healthcare organizations to emulate the advanced digital health ecosystems of these two Nordic frontrunners. According to the survey, 94% of respondents identified Denmark's comprehensive national health portal, as a model for delivering centralized patient records and seamless data exchange. Finland's Kanta platform similarly emerged as a key inspiration, cited by 90% of healthcare executives for its robust nationwide interoperability and extensive patient record accessibility. The survey also recognized standout EHR technology vendors contributing significantly to these Nordic success stories. Epic Systems, utilized by major hospitals and health regions in Denmark, was ranked highly for its interoperability performance and scalability across diverse clinical environments. TietoEVRY and CGI, prominent in the Finnish healthcare market, received notable recognition for their roles in facilitating robust connectivity and patient-centric record management through Finland's Kanta service. The report also highlighted Germany and Italy as the European nations with high EHR adoption rates yet struggling most significantly with interoperability and patient record access. Survey respondents identified primary reasons for these challenges as fragmented regional systems, lack of centralized governance, varying data standards, and insufficient investment in integrated digital health infrastructure. Providers in these countries reported an average interoperability satisfaction score of just 18%, significantly lower than Nordic benchmarks. According to respondents, responsibility for these challenges is shared: 86% cited government policy and funding issues, 21% pointed to vendor limitations in offering interoperable solutions, and 80% attributed the problems to provider reluctance or inability to implement cohesive digital strategies. "European IT leaders are closely analyzing the strategic frameworks, governance structures, and advanced technology models pioneered by Denmark and Finland," said Douglas Brown, founder of Black Book Market Research. "Their proven success with interoperability standards, comprehensive EHR adoption, and seamless data integration is inspiring other European health systems to accelerate their digital transformations with secure data exchange and patient-centric solutions." Further survey insights highlighted specific adoption trends: 91% of surveyed executives emphasized the importance of centralized national infrastructures to enable seamless EHR integration. 84% noted the critical role of stringent data standardization, including widespread adoption of HL7 FHIR standards. 60% of respondents are now accelerating plans for patient-access portals inspired by the Danish and Finnish approaches. "Denmark and Finland offer powerful examples of how cohesive digital health strategies improve patient care and operational efficiency," added Brown. "Vendors succeeding in these markets are proving vital to replicating these results throughout Europe." Top Client-Rated Interoperability Solutions Vendors at HIMSS 25 EU Attendees of HIMSS25 Europe in Paris are encouraged to visit four leading interoperability vendors highly rated in recent Black Book IT user surveys across Europe. These vendors are recognized for their advanced solutions driving seamless connectivity, comprehensive data integration, and patient-centric interoperability. Each demonstrates notable success in enabling secure data exchange, facilitating real-time patient information access, and empowering healthcare organizations to optimize patient outcomes and operational efficiency. Visitors can expect compelling demonstrations highlighting the robust capabilities and proven successes these vendors have achieved within Europe's most digitally advanced healthcare environments: InterSystems Hyland Dedalus Epic Systems About Black Book Market ResearchBlack Book Market Research is a leading global independent research firm providing unbiased, client-driven evaluations of healthcare technology and services. Black Book rankings are based entirely on user feedback and customer satisfaction data, offering strategic insights to healthcare providers, payers, vendors, and investors. For more information, visit Contact Information Press Office research@ SOURCE: Black Book Research View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
4 hours ago
- Associated Press
European Health IT Leaders Look to Denmark and Finland as Models for EHR Interoperability and Patient Access, Black Book Survey Reveals
Ahead of Next Week's HIMSS 25 Europe in Paris, Attendees Look to Top Interoperability Vendors for Solutions PARIS, FRANCE / ACCESS Newswire / June 7, 2025 / Black Book Market Research today released findings from its latest survey highlighting the influence of Denmark and Finland on Electronic Health Record (EHR) interoperability and patient access initiatives across Europe. Conducted among 312 healthcare IT leaders from 8 higher tech-adoption European nations, the study underscores the strategic shift among healthcare organizations to emulate the advanced digital health ecosystems of these two Nordic frontrunners. According to the survey, 94% of respondents identified Denmark's comprehensive national health portal, as a model for delivering centralized patient records and seamless data exchange. Finland's Kanta platform similarly emerged as a key inspiration, cited by 90% of healthcare executives for its robust nationwide interoperability and extensive patient record accessibility. The survey also recognized standout EHR technology vendors contributing significantly to these Nordic success stories. Epic Systems, utilized by major hospitals and health regions in Denmark, was ranked highly for its interoperability performance and scalability across diverse clinical environments. TietoEVRY and CGI, prominent in the Finnish healthcare market, received notable recognition for their roles in facilitating robust connectivity and patient-centric record management through Finland's Kanta service. The report also highlighted Germany and Italy as the European nations with high EHR adoption rates yet struggling most significantly with interoperability and patient record access. Survey respondents identified primary reasons for these challenges as fragmented regional systems, lack of centralized governance, varying data standards, and insufficient investment in integrated digital health infrastructure. Providers in these countries reported an average interoperability satisfaction score of just 18%, significantly lower than Nordic benchmarks. According to respondents, responsibility for these challenges is shared: 86% cited government policy and funding issues, 21% pointed to vendor limitations in offering interoperable solutions, and 80% attributed the problems to provider reluctance or inability to implement cohesive digital strategies. 'European IT leaders are closely analyzing the strategic frameworks, governance structures, and advanced technology models pioneered by Denmark and Finland,' said Douglas Brown, founder of Black Book Market Research. 'Their proven success with interoperability standards, comprehensive EHR adoption, and seamless data integration is inspiring other European health systems to accelerate their digital transformations with secure data exchange and patient-centric solutions.' Further survey insights highlighted specific adoption trends: 91% of surveyed executives emphasized the importance of centralized national infrastructures to enable seamless EHR integration. 84% noted the critical role of stringent data standardization, including widespread adoption of HL7 FHIR standards. 60% of respondents are now accelerating plans for patient-access portals inspired by the Danish and Finnish approaches. 'Denmark and Finland offer powerful examples of how cohesive digital health strategies improve patient care and operational efficiency,' added Brown. 'Vendors succeeding in these markets are proving vital to replicating these results throughout Europe.' Top Client-Rated Interoperability Solutions Vendors at HIMSS 25 EU Attendees of HIMSS25 Europe in Paris are encouraged to visit four leading interoperability vendors highly rated in recent Black Book IT user surveys across Europe. These vendors are recognized for their advanced solutions driving seamless connectivity, comprehensive data integration, and patient-centric interoperability. Each demonstrates notable success in enabling secure data exchange, facilitating real-time patient information access, and empowering healthcare organizations to optimize patient outcomes and operational efficiency. Visitors can expect compelling demonstrations highlighting the robust capabilities and proven successes these vendors have achieved within Europe's most digitally advanced healthcare environments: About Black Book Market Research Black Book Market Research is a leading global independent research firm providing unbiased, client-driven evaluations of healthcare technology and services. Black Book rankings are based entirely on user feedback and customer satisfaction data, offering strategic insights to healthcare providers, payers, vendors, and investors. For more information, visit Contact InformationPress Office 8008637590 SOURCE: Black Book Research press release
